Guideline heart failure therapy was linked to lower mortality after 65, but frail patients miss out

Design

Systematic review and meta-analysis of 34 studies

Population

92,916 patients aged ≥65 with HFrEF

Primary outcome

All-cause mortality with vs without guideline-directed therapy

Effect

HR 0.69 (95% CI 0.64–0.74); bradycardia RR 3.98 (2.72–5.82)

This systematic review and meta-analysis pooled 34 studies with 92,916 patients aged 65 or older with heart failure with reduced ejection fraction, comparing those who received guideline-directed medical therapy with those who did not. Most studies assessed at least one drug class; only three looked at three classes, and none at all four.

Guideline therapy was associated with lower mortality (HR 0.69, 95% CI 0.64–0.74), though heterogeneity was substantial (I² 71%). Frail patients were less likely to receive it (RR 0.63, 0.45–0.89). Beta-blockers raised the risk of bradycardia about fourfold (RR 3.98), but hypotension, acute kidney injury and hypoglycaemia were not more frequent.

Most data are observational, so part of the benefit will reflect healthier patients being treated. Even so, the feared harms — low blood pressure, kidney injury — did not show up. The prescribing lesson is to start and titrate carefully, watch heart rate, and not let age or frailty alone rule treatment out.

• Offer guideline-directed therapy for reduced ejection fraction to older patients; age alone is not a contraindication.
• Start at low doses and titrate one drug at a time, checking blood pressure, potassium and creatinine.
• Monitor heart rate on beta-blockers — bradycardia was about four times more likely in older patients.
• Assess frailty, but use it to shape titration speed rather than to withhold therapy.
• Review for drugs that add to bradycardia or hypotension, such as digoxin, non-dihydropyridine calcium blockers and alpha-blockers.

Why it matters

It challenges the reflex to under-treat older heart failure patients for fear of side effects that did not materialise.

Don't overread it

Mostly observational data with high heterogeneity; the survival benefit is an association, and four-drug therapy was not studied.

The statistics, in plain English

A hazard ratio of 0.69 means about 31% lower mortality in those who received therapy. An I² of 71% means results varied a lot between studies, so the pooled figure is an average of different effects. Because most studies were observational, treated patients may simply have been healthier.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.